Oncotarget
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Learn about our FREE
Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.
Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.
Impact Journals is a member of the Society for Scholarly Publishing.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.
10.18632/ONCOTARGET.15422 |
10.18632/ONCOTARGET.23208 |
10.18632/ONCOTARGET.27700 |
10.18632/ONCOTARGET.9787 |
10.18632/ONCOTARGET.28634 |
Most popular Oncotarget DOIs, measured by the number of times each DOI was successfully resolved.
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025. Learn more here and here.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds. Learn more.
Editors-in-Chief
Wafik S. El-Deiry, MD, PhD, FACP
American Cancer Society Research Professor
Director, Legorreta Cancer Center at Brown University
Associate Dean, Oncologic Sciences
Warren Alpert Medical School, Brown University
Chair, WIN Consortium for Personalized Cancer Medicine
Andrei V. Gudkov, PhD, DSci, Professor and Garman Family Chair in Cell Stress Biology, Senior Vice President for Basic Research of Roswell Park Comprehensive Cancer Center (RPCI), Buffalo, NY. His academic degrees in experimental oncology and molecular biology were received in former USSR from National Cancer Center and Moscow State University. He is co-founder and Chief Scientific Officer of Cleveland BioLabs, Inc. and Tartis, Inc. His area of general research interest includes drug discovery, gene discovery, molecular targets for cancer treatment.
Mikhail V. Blagosklonny, M.D., Ph.D., Professor, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Dr. Blagosklonny is author of over 200 articles in peer-reviewed journals. He is Associate Editor of Cancer Res, Cell Death Differ, Cancer Biol Ther, Autophagy, Int J Cancer, Am J Pathology, PLOS ONE and Editor-in-Chief of Cell Cycle. His research interests range from molecular and cellular biology to clinical investigations and include signal transduction, cell cycle, cellular senescence, anticancer therapeutics with emphasis on translation of basic science into new anticancer strategies Recently, he extended the study of signal transduction pathways from cancer to aging, revealing potential targets for slowing down aging and age-related diseases.
Editorial Board
New members as of July 2024:
Prof. Humaid Obaid Al-Shamsi is the Chief executive officer of Burjeel cancer institute in Abu Dhabi, UAE, President of the Emirates Oncology Society, Lead of the Gulf Cancer Society, Full Professor of Oncology at the Ras al Khaimah Medical and Health Sciences University, Ras al Khaimah, UAE and an adjunct Professor of Oncology at the College of Medicine at the University of Sharjah.
He is the first Emirati to be promoted to a professor in oncology in the UAE. He is also the Chairman for Colorectal Cancer in the MENA region, appointed by the prestigious National Comprehensive Cancer Network®. He is also the only member of Lung Cancer Policy Network in the MENA region that aims to advance lung cancer research and screening globally.
He is the Chairman of the Oncology and Hematology Fellowship Training Program for the National Institute for Health Specialties in the United Arab Emirates. He is the only member in GCC in the WIN Consortium which comprised of organizations representing all stakeholders in personalized cancer medicine globally.
He is board-certified in both Internal Medicine and Oncology from the UK , USA(ABIM), and Canada (FRCPC), he is also has been awarded the FRCP(London) in 2023 and he will be awarded FRCP Glasgow next week inshalla.
He is the only physician in the UAE with a subspecialty fellowship certification and training in Gastrointestinal Oncology and the first Emirati to train and complete a clinical post-doctoral fellowship in Palliative Care. He was an Assistant Professor at the University of Texas MD Anderson Cancer Center between 2014 and 2017.
He has published more than 140 peer-reviewed articles in JAMA Oncology, Lancet Oncology, The Oncologist, BMC Cancer, and many others. His area of expertise including precision oncology and cancer care in the UAE. In 2016 he published with his group from MD Anderson the JCO paper describing a new distinct sub group of CRC , NON V600 BRAF mutated CRC. In 2022, he published the first book about cancer research in the UAE and also the first book about cancer in the Arab World, both of which were launched at Dubai Expo 2020. “Cancer in the Arab Wolrd ” which has been downloaded more than 450,000 times in their first 18 months of publication to be the ultimate source of cancer data in the Arab region.
He also published the first comprehensive book about cancer care in the UAE which is the first book in UAE history to document the cancer care in the UAE with many topics addressed for the first time e.g neuroendocrine tumors in the UAE.
He is passionate about advancing cancer care in the UAE and the GCC and has made significant contributions to cancer awareness and early detection for the public using social media platforms. He is considered as the most followed oncologist in the world with over 300,000 subscribers across his social media platforms (Instagram , Twitter , LinkedIn and TikTok).
In 2022, he was awarded the prestigious Feigenbaum Leadership Excellence Awards from Sheikh Hamdan Smart University for his exceptional leadership and research, as well as the Sharjah Award for Volunteering. He was also named the Researcher of the Year in the UAE in 2020 and 2021 by the Emirates Oncology Society.
In May 2024 HH Sheikh Mansoor Bin Zayed alnahyan Vice President of the United Arab Emirates awarded him the first place in UAE Nafis program for outstanding leadership in private sector across all business and medical disciplines.
Bedside his clinical & administrative duties , he is engaged in education & research training for medical trainees at different levels of their training to enhance their clinical and research skills.
Prof.Alshamsi mission is to advance cancer care in the UAE & the MENA region and make cancer care accessible to everyone in need around the globe.
Trever Bivona, MD, PhD, Professor, Department of Medicine, Hematology/Oncology division, Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA
Dr. Trever Bivona is a cell and molecular biologist and a medical oncologist. He received his MD and PhD degrees from NYU School of Medicine, followed by internal medicine training at the Brigham and Women’s Hospital/Harvard Medical School in Boston, and medical oncology and post-doctoral research training at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Bivona then joined the faculty at the University of California, San Francisco in 2011 where he is currently a Professor in the Department of Medicine, Hematology/Oncology division, and the Department of Cellular and Molecular Pharmacology, and a member of the Helen Diller UCSF Comprehensive Cancer Center. Dr. Bivona is also an appointed Senior Investigator at the Chan-Zuckerberg Biohub, San Francisco. Dr. Bivona directs a basic and translational research program investigating oncogene signaling pathways and the molecular basis of response and resistance to cancer therapeutics, with a major focus on kinase and RAS signaling. Recent work by Dr. Bivona and colleagues uncovered a new form of oncogenic kinase and RAS signaling through liquid-liquid phase separation and biomolecular condensation. Dr. Bivona is currently Principal Investigator of the NIH/NCI Bay Area and Anderson Acquired Resistance to Therapy Network (ARTNet) Center. He received a NIH Director’s New Innovator Award and is an elected member of the American Society for Clinical Investigation.
Phillip Buckhaults, Ph.D., Professor, Drug Discovery & Biomedical Sciences (DDBS) College of Pharmacy, University of South Carolina, Columbia, SC
Fred Bunz, Ph.D., M.D., Associate Professor, department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore MD
Dr. Bunz earned his M.D. and Ph.D. in the Medical Scientist Training Program at Stony Brook University, was a Howard Hughes postdoctoral fellow at Johns Hopkins, and is currently an Associate Professor in the department of Radiation Oncology and Molecular Radiation Sciences at the Sidney Kimmel Comprehensive Cancer Center. His research interests are centered on the signaling molecules and pathways that are activated by DNA damage and viral infection. The long term goal of this work is to better understand how current therapies work and to develop new and improved cancer treatments. A recent area of interest is the development of oncolytic viruses. Dr. Bunz also serves as a co-director of the Oncology Tissue and Imaging Core at the Kimmel Cancer Center and co-director of Admissions for the program in Cellular and Molecular Medicine, the largest PhD training program at the Johns Hopkins School of Medicine. He is the author of Principles of Cancer Genetics, a widely used textbook currently in its 3rd edition.
Benedito A Carneiro, MD, MS is a Medical Oncologist and Clinical Investigator renowned for his expertise in early drug development and first-in-human trials exploring novel therapeutics for solid tumors and genitourinary cancers. Dr. Carneiro serves as the founder and Director of the Cancer Drug Development Program (Phase I) and Director of Clinical Research at the Brown University Health Cancer Institute. He is also Associate Director of the Division of Hematology/Oncology, Co-Leader of the Cancer Therapeutics Program at the Legorreta Cancer Center at Brown University and Associate Professor of Medicine. He leads numerous first-in-human (phase I) clinical trials evaluating novel treatments for advanced solid tumors, including kidney, bladder, prostate, lung, pancreas, and colon cancers. Dr Carneiro's research spans clinical and translational research efforts, exploring novel immunotherapies, genomic-driven treatment strategies, cellular therapy, and the identification of therapeutic targets and biomarkers of treatment response and resistance mechanisms in collaboration with translational scientists.
Dr. Carneiro has expertise in the mechanisms of cell death (apoptosis) and its interface with anti-tumor immune response and novel agents targeting tumors with defects in DNA repair mechanisms. Ongoing research projects investigate novel strategies to treat advanced prostate cancer with immunotherapies and overcoming therapy-induced senescence. He has authored over 110 articles in peer-reviewed journals and contributed to multiple book chapters. He is an active member of the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the American Association of Cancer Research (AACR). He represents the Legorreta Cancer Center at the WIN (Worldwide Innovative Networking in Personalized Cancer Medicine) Consortium. He is an active AACR Annual Meeting Clinical Trials Committee member and has participated in the ASCO Annual Meeting Scientific Program Committee.
Jonathan Chernoff, MD PhD, Director, Fox Chase Cancer Center, Philadelphia, PA
Dr. Chernoff has devoted his research career to understanding how cells receive and interpret signals, and how this process in corrupted in cancer. In particular, he focuses on the regulation of signal transduction by phosphorylation, with the overarching goal to understanding how these pathways are rewired in cancer, and their implications for the development, spread, and resistance of solid tumors to therapy.
His group has made important discoveries in three signaling pathways: Rho-family small GTPases, Hippo, and Insulin signaling, through discoveries and subsequent work on the STE20 kinases PAK and MST, and the protein tyrosine phosphatase PTP1B, respectively. He has broad expertise in molecular biology, biochemistry, cell biology, proteomics, and mouse models of cancer. Dr. Chernoff is the author of more than 200 publications and he was elected as a fellow of the American Association for Advancement of Science in 2017.
Dr. Chun is a Radiation Oncologist at the MD Anderson Cancer Center where he serves as Director of Radiation Oncology Clinical Research for the MD Anderson Houston Area Locations. He has received grant funding from the National Cancer Institute (NCI) as Principal Investigator and has widely published on the multidisciplinary management of aerodigestive malignancies in journals such as the Lancet, the Journal of Clinical Oncology and JAMA Oncology. Dr. Chun is highly active with NRG Oncology and was responsible for launching their podcast which was the first ever established by an NCI cooperative group.
Nathan Dolloff, PhD, Associate Professor, Medical University of South Carolina, Director of Entrepreneurship, Hollings Cancer Center, MUSC Office of Innovation, Chief Technology Officer, Zucker Institute for Innovation Commercialization, Charleston, SC
Nathan Dolloff is PI of an NIH-funded cancer therapeutics research program at the Medical University of South Carolina (MUSC) in Charleston, SC. In addition to his research program, Dr. Dolloff serves as Chief Technology Officer for MUSC’s technology commercialization office, the Zucker Institute for Innovation Commercialization. As part of that role, he leads entrepreneurship initiatives for the NCI designated MUSC Hollings Cancer Center and the MUSC Office of Innovation. He is founder of Leukogene Therapeutics, Inc., which is a Charleston-based spin-out company developing an MHC class II targeted (M2T™) therapeutic cancer vaccine platform for some of the deadliest cancers, including pancreatic cancer and Acute Myelogenous Leukemia (AML). M2T™ directs tumor associated antigens to antigen presenting cells thereby promoting their presentation to the immune system and driving an anti-tumor immune response. Leukogene has raised over $6M to date and has been awarded multiple Phase I and Phase II SBIR/STTR grants from NIH/NCI. Earlier in his career, Dolloff led projects that produced multiple cancer drug candidates, including olaratumab/LARTRUVO, CDK9 inhibitors, dual CDK1/GSK3beta inhibitors, and the discovery of the PDI inhibitor, LTI6426. Dolloff is an MUSC Eminent Scholar and was MUSC’s Innovator of the Year in 2018. He is an inventor on numerous issued and pending patents, author of >40 peer reviewed journal articles and book chapters, fellow of the National Academy of Inventors, and former Research Scholar of the American Cancer Society.
Peiwen Fei, M.D., Ph.D., Professor of Cancer Biology. University of Hawai‘i Cancer Center, University of Hawai‘i at Mānoa
Dr. Peiwen Fei has been in the tumor-suppression field of basic cancer research on DNA Damage Response (DDR) / Fanconi Anemia (FA) Signaling and TP53 signaling for more than two decades. Her research team often reports new findings, constantly opening new niches of investigation. These have been highlighted not only in several scientific news media (ScienceDaily, Pubadvanced, World Biomedical Frontiers, and Global Medical Discovery), but also via invited reviews. Beyond this area of cancer research, she has also recently emerged as a leader in studying cancer health disparities associated with some racial/ethnic populations, including Native Hawaiians / Pacific Islanders.
Dr. Hazlehurst is professor of Pharmaceutical Sciences at West Virginia University. Her research focus is delineating cancer vulnerabilities in the context of the tumor microenvironment. Her work has led to validation of novel targets as well as pharmacological approaches to further validate and define the therapeutic window for clinical development. In addition to her academic career she is co-founder of Modulation Therapeutics which is now a clinical stage therapeutic company where she has gained more experience in the drug development pathway. She has received grant funding from National Cancer Institute as principle investigator and has served on multiple NCI study sections.
Elizabeth (Lisa) Petri Henske is the Director of the Center for LAM Research and Clinical Care at Brigham and Women's Hospital, Professor of Medicine at Harvard Medical School, and a practicing medical oncologist at the Dana-Farber Cancer Institute. She earned her undergraduate degree summa cum laude from Yale and her MD from Harvard, followed by residency and fellowship training at Massachusetts General Hospital. Her laboratory discovered that lymphangioleiomyomatosis (LAM) is caused by mutations in the tuberous sclerosis complex (TSC) genes and was the first to discover that the TSC1 and TSC2 proteins physically interact. Her research laboratory is focused on the cellular, metabolic, and immunologic mechanisms underlying the pathogenesis and therapy of tuberous sclerosis complex (TSC) and rare renal tumors, including angiomyolipomas and chromophobe renal cell carcinoma. She has led clinical trials in LAM and is supported by grants from the NCI, NHLBI and NIDDK.
Justin D. Lathia, PhD; Professor, Lerner Research Institute, Cleveland Clinic; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Scientific Director, Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic; Molecular Oncology Co-Leader, Case Comprehensive Cancer Center
Dr. Justin Lathia leads a translational cancer stem cell research laboratory with a focus on understanding how cancer stem cells interact with their surrounding microenvironment as well as one another with the goal of identifying unique pathways for therapeutic development and a recent focus on sex differences in glioblastoma. Work in the Lathia laboratory has resulted in multiple Phase 1 clinical trials aimed at targeting myeloid-derived suppressor cells that interact with cancer stem cells to suppress the immune system in glioblastoma or cancer stem cell specific therapeutic vulnerabilities. Dr. Lathia has co-authored over 260 publications. Dr. Lathia also serves on the editorial board for Cell Reports, Cancer Research, and Neuro-Oncology.
Sean Lawler Ph.D leads the Brain Cancer Therapy Lab in the Department of Pathology and Laboratory Medicine at Brown University. He is co-Director of the Brain Cancer Research Group at Legorreta Cancer Center. The Lawler Lab investigates therapeutic approaches for the treatment of Brain Cancer, from preclinical models, to the analysis of data from patient tumors, with the goal of developing the next generation of therapeutic approaches for these extremely challenging diseases. Sean Lawler obtained his PhD from the University of London in 1992, and specialized in mammalian signal transduction mechanisms during his post-doctoral training at UCSF, INSERM and the University of Dundee, before faculty appointments at Massachussetts General Hospital, The Ohio State University, the University of Leeds, and Brigham and Women's Hospital where he has developed an expertise in translational approaches for brain tumor therapy.
At MDACC, she served as Chair for the Clinical Research for the IBC program, Chair of the TMP-CRG, and SRC group 3 member. At Baylor College of Medicine (BCM) in December 2020, as a Tenured Associate Professor, Director of Translational Research, and Associate Director of Clinical Science at the Breast Center, she further strengthened her scientific portfolio by taking advantage of the strong laboratory infrastructure and developed productive collaborations as both the administrative core Clinical Lead and the Project 1 trial lead for the Breast SPORE project at BCM. During this tenure, she led the clinical core part of the BCM Breast SPORE and its Project 1, organizing different parties. Now back at MDACC, she is the Director of Translational Research for the Morgan Welch IBC Research and Clinic Program, and Section Chief for Translational Research of the Department of Breast Medical Oncology. At the national level, she serves as a reviewer for several grant programs including the DOD, CME committee member for the AACR, and as a member of several committees and representative of ASCO.
Jia (Jenny) Liu, MD PhD FRACP, Translational Lead, Early Phase Unit, The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW Australia.
As the Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, she oversees and manages the design and execution of early phase clinical trials for novel cancer therapeutics, with a focus on head and neck cancer. Dr Liu graduated with BSc(Med)Hons Class 1, MD (university medal) and PhD from University of New South Wales in 2014, and is currently a member of the Medical Oncology Group of Australia Executive Committee and Chair of the National Oncology Mentorship Program. She has a strong track record in translational research in epigenetics, proteomics and survivorship, alongside her clinical expertise with drug development and is currently principal investigator on over 15 trials, and leads investigator-led trials at TKCC in collaboration with scientists, cooperative groups and industry. She has been the recipient of over 10 grants and 10 prizes/awards and has been a speaker to multiple national and international conferences including ASCO, ESMO GI and ASTRO.
Hui-Wen Lo, Ph.D., McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas
Dr. Lo is UTHealth Houston Distinguished Professor in Neuro-Oncology, Professor of Neurosurgery with tenure, Vice Chair of Research in the Department of Neurosurgery, and the Director of the Metastatic Brain Tumor Research Program at McGovern Medical School, University of Texas Health Science Center at Houston. Dr. Lo started her independent academic career at Duke University School of Medicine 2006 as a tenure-track Assistant Professor. During 2014-2022, Dr. Lo was a tenured Associate Professor and Professor of Cancer Biology at Wake Forest School of Medicine, as well as, the Associate Director for Shared Resources Management and Associate Director for Basic Sciences at the NCI-designated Wake Forest Baptist Comprehensive Cancer Center. She is a basic and translational cancer biologist with more than 30 years of experience in conducting cancer-related studies. She has published >120 peer-reviewed publications. Her research is innovative and her scientific discoveries have led to two patents and one clinical trial. Her laboratory has been continuously funded by many NIH and DoD grants, as well as, funding from private foundations in the past 18 years.
Emil Lou, M.D., Ph.D, FACP, Professor with tenure, Department of Medicine, Division of Hematology, Oncology and Transplantation, Department of Medicine and Graduate Faculty Program member in the Integrative Biology and Physiology Program (IBP) at the University of Minnesota
Dr. Lou received his M.D. and Ph.D. degrees (Microbiology and Immunology) from SUNY Upstate Medical University in 2004. He performed his residency training in Internal Medicine at Duke University Medical Center and then subsequently completed his Medical Oncology and Hematology fellowship at the Memorial Sloan-Kettering Cancer Center in 2010. He also completed an additional fellowship in Neuro-Oncology at the Preston Robert Tisch Brain Tumor Center at Duke. Dr. Lou, a diplomate of the American Board of Internal Medicine, is board certified in Medical Oncology and Internal Medicine. In addition he is also board certified in Neuro-Oncology through the United Council for Neurologic Subspecialties. Dr. Lou’s clinical practice focuses on patients with advanced gastrointestinal cancers, and his research program centers on advancing understanding of clinical cancer biology of solid tumors. His lab investigates the role of intercellular communication on tumor heterogeneity and impact on cancer cell invasion, progression, tumor recurrence, and chemotherapy resistance, with special focus on tunneling nanotubes (TNTs), long cellular protrusions that act as skyways to create cellular networks for communication and coordination.
Dr. Maitra is a Professor of Pathology and Translational Molecular Pathology, and Scientific Director of the Pancreatic Cancer Research Center at UT MD Anderson Cancer Center, Houston (since August 2013). Dr. Maitra is the Principal Investigator of an NCI-funded laboratory dedicated to pancreatic cancer research. The arc of his research career has been defined by contributions made in the spheres of genetics and molecular pathology of pancreatic cancer and its precursor lesions, in both human and cognate mouse models of pancreatic neoplasia. Dr. Maitra is deeply committed towards identifying and implementing translational research opportunities in pancreatic cancer that can improve the survival of patients stricken with this disease, with a particular focus on early detection and cancer interception.
Ruben Mesa, MD, President, Atrium Health Levine Cancer, Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Dr. Mesa is the President of Atrium Health Levine Cancer, the Executive Director of the NCI Comprehensive Cancer based at Wake Forest Baptist; the Vice Dean for cancer programs at Wake Forest School of Medicine Enterprise Cancer Service Line Atrium Health and Senior Vice President for Atrium Health where he oversees all efforts for cancer practice, education and research across Atrium Health (the Southeast Region for Advocate Health the 5th largest health system in the USA). From 2017-2023 Mesa was the Executive Director of the NCI Designated Mays Cancer Center at UT Health San Antonio MD Anderson where he developed and grew the cancer service line, co-led the development and construction of a new cancer focused hospital, grew cancer faculty, peer reviewed funded research and successfully renewed the NCI designation in 2020. Mesa practiced hematology at Mayo Clinic (MN 2002-2009, AZ 2009-2017) and was Chair of Hematology & Medical Oncology and Deputy Director of the Mayo Clinic Comprehensive Cancer Center.
Mesa is an international expert in hematologic cancers, who has dedicated his life’s work to research and drug development for myeloproliferative neoplasms and led/co-led the development of six drugs that have been FDA approved for myeloproliferative neoplasms and was the inaugural panel chair of the NCCN guideline panel for the first USA guidelines for MPNS. Mesa is passionate about advancing cancer health equity and increasing minority patients’ participation in cancer clinical trials, implement a mandate that each new trial at the Mays Cancer Center had a minority accrual plan, and in March 2022, he testified on the importance of clinical trial diversity before the House Committee on Energy and Commerce. Mesa also co-led the Mays Cancer Center’s biennial Advancing the Science of Cancer in Latinos Conference held in San Antonio.
Steven A. Rosenzweig, Ph.D., Professor of Pharmacology and Immunology Medical University of South Carolina
Dr. Rosenzweig is Professor of Pharmacology and Immunology at the Medical University of South Carolina, Associate Director of Shared Resources at Hollings Cancer Center. Dr. Rosenzweig obtained his PhD from the University of Toronto and carried out postdoctoral studies at Yale University School of Medicine. Recruited to MUSC in 1991 due to his interests and accomplishments in cell signaling research, he has made seminal contributions to the structure and function of peptide hormones, growth factors and their receptors. More recent research has focused on the structure and function of the insulin-like growth factor binding proteins (IGFBPs) and their potential as natural IGF antagonists and thus cancer therapeutics. This led to his current interest in using a portion of the C-terminus of IGFBP2 in generating a nanotube platform for the delivery of therapeutics and biologics to difficult to reach locations in a variety of cancers and other diseases. Included in the many awards he has received, is the 11th Annual Piero P. Foà Endowed Lecture in 2015.
Dr. Yashbir Singh is an Assistant Professor of Radiology at Mayo Clinic in Rochester, MN, USA. He holds an ME and PhD, with his doctorate completed in Taiwan on a Taiwanese Government scholarship. Dr. Singh's research focuses on applying deep learning-based AI algorithms and topological data analysis to medical imaging, aiming to improve patient care through enhanced image interpretation and identification of new disease biomarkers. His academic journey includes a DAAD fellowship from Germany, and positions as a visiting scientist at Harvard Medical School's Cardiac Surgery Department and as a medical scientist at West Virginia University's Heart and Vascular Institute. Dr. Singh is part of the Early Career Reviewer program at the NIH's Center for Scientific Review.
Dr. Singh has received several accolades, including recognition as a top reviewer by the European Society of Radiology and being a finalist for the Arthur E. Weyman Young Investigator's Award from the American Society of Echocardiography. He has authored numerous scientific publications and received travel grants from the New York Academy of Sciences and Stanford University.
Dr. Warfel is an Associate Professor of Cellular and Molecular Medicine at the University of Arizona. His research is focused on understanding how factors in the tumor microenvironment impact tumor cells metastasis and drug resistance, with the goal of identifying unique pathways for therapeutic development. Work from the Warfel laboratory has advanced our understanding of HIF-independent signaling pathways that are activated in response to hypoxia. Most notably, Dr. Warfel’s research focusing on PIM kinases as expanded how we view PIM kinases in disease and as potential therapeutic targets. Dr. Warfel has received grant funding from the American Lung Association, American Cancer Society, and Department of Defense as Principal Investigator is has published over 40 peer-reviewed journal articles and book chapters.
Cory Abate-Shen, PhD, Professor, Director of Research, Department of Pathology, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University, NY
Frederick W. Alt, Ph.D., member of the National Academy of Sciences, Professor, Harvard Medical School
Dr. Alt is also Investigator, Howard Hughes Medical Inst., Charles A. Janeway Professor of Pediatrics, HMS, Scientific Director, CBRI Institute for Biomedical Research.Fred Alt received a PhD from the Department of Biological Sciences at Stanford University. He is a Howard Hughes Medical Institute investigator, a member of the National Academy of Sciences and the American Academy of Sciences. He is the recipient of He is the recipient of the 2003 Excellence in Mentoring Award from the American Association of Immunologists and the 2004 Clowes Memorial Award from the American Association of Cancer Research. Editorial Boards: Mol. and Cell. Biology; Advances in Immunology; International Immunology; J. Exp. Med.; Current Opinion in Immunology; Immunity (founding Co-editor; 1993-present); Molecular Medicine (Contributing editor; 1997-present); Faculty of 1000 (co-head, Immunology). Honors and Awards: Fox Award, Stanford Univ. (1973); Hirschl Award (1983); Searle Scholar; (1983) Mallinckrodt Scholar; (1984); NIH Merit Award (1991); National Academy of Sciences (1994); American Academy of Microbiology (1994); American Academy of Arts and Sciences (1994); Associate (Foreign) Member, European Molecular Biology Organization (1999); Excellence in Mentoring Award,Association of Immunologists (2003); American Association of Cancer Research B.H.A. Clowes Award (2004); Rabi Shai Shacknai Memorial Prize in Immunology & Cancer Research (2005); Leukemia & Lymphoma Society de Villiers International Achievement Award (2005), Pasarow Foundation Prize in Cancer Research (2005); Irvington Institute Scientific Leadership in Immunology Award (2005); Establishment of Frederick W. Alt Award for New Discoveries in Immunology by the Irvington Institute (2006); National Cancer Institute Alfred Knudson Award in Cancer Genetics(2007).
Dario Altieri, MD, Robert and Penny Fox Distinguished Professor, Director, The Wistar Institute Cancer Center, Executive Vice President, Chief Scientific Officer, The Wistar Institute, Philadelphia, PA.
Dafna Bar-Sagi, Ph.D., Professor and Chair, Department of Biochemistry New York University School of Medicine, 550 First Avenue New York, NY 10016
After earning her undergraduate and master's degree in Biochemistry from Bar-Ilan University in Israel, Dr. Bar-Sagi completed a PhD in Cell Biology at the State University of New York, Stony Brook (SUNY). She received postdoctoral training and eventually served as Senior Staff Investigator at Cold Spring Harbor Laboratory in Long Island. In 1995, she joined the faculty of the Department of Molecular Genetics and Microbiology at SUNY and served as Department Chair from 2003-2006. She relocated to New York University Medical Center in 2006, where she is currently Professor and Chair of the Department of Biochemistry. Dr. Bar-Sagi has published over 100 peer-reviewed articles in leading scientific journals. In 2008, she was appointed Chair of the Scientific Advisory Board of the Pancreatic Cancer Action Network.
Jiri Bartek, MD., Ph.D., Professor, Head, Department of Cell Cycle and Cancer Danish Cancer Society, Deputy Director, Centre for Genotoxic Stress Research Cancer Institute of Cancer Biology, Copenhagen
He received his M.D. degree from Palacky University in Olomouc, and his Ph.D. degree in Cell Biology from the Institute of Molecular Genetics in Prague, Czech Republic. His main research interests include the molecular mechanisms of mammalian cell-cycle control and responses to DNA damage, and the cancer-predisposing aberrations of these regulatory pathways.
Jiri Bartek has a total of more than 320 publications in peer reviewed journals (about 30-40 in Nature, Science and Cell), with over 26.000 citations. He is currently member of the editorial boards of 10 high-medium impact biomedical journals and has won a number of awards including: (1991,1992) Czech Medical Association Award, (2000) Elected EMBO member, (2002) A. Benzon Prize, (2003) Novo Nordisk Prize, (2003) G.J. Mendel Medal, (2006) Danish Cancer Society Prize
Stephen B. Baylin, M.D., Professor, Deputy Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Virginia and DK Ludwig Professor of Oncology, Baltimore, MD, USA
Dr. Stephen B. Baylin is professor of oncology and medicine, director of the cancer biology program at the oncology center, and the Virginia and D.K. Ludwig Professor of Cancer Research at The Johns Hopkins University School of Medicine, and the associate director for research at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Dr. Baylin has been a member of committees of the American Cancer Society and the National Institutes of Health, and his multiple honors include a Research Career Development Award from the National Institutes of Health. For the last 20 years, Dr. Baylin has studied the role of epigenetic gene silencing in the initiation and progression of human cancer.
Mina J. Bissell, PhD, member of the National Academy of Sciences, Distinguished Scientist, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkley, CA
Mina Bissell has been recognized for her lifetime contributions to the fields of breast cancer research, the enhanced role of extracellular matrix (ECM) and the nucleus environment to gene expression in normal and malignant tissues. These works have ushered and have changed some central paradigms that have strengthened the importance of context in the development of cancer.
Bruce R. Blazar, M.D., Professor, University of Minnesota, Minneapolis MN
Bruce R. Blazar is a Regents Professor of Pediatrics, and Chief of the Pediatric Blood and Marrow Transplantation Program. Dr. Blazar is the Director of the University of Minnesota's Clinical and Translational Science Institute.
Kenneth Cowan, M.D., Ph.D., Professor, University of Nebraska Medical Center, Omaha, NE, Director, Eppley Institute, Director, UNMC Eppley Cancer Center.
Dr. Cowan has authored more than 240 papers for scientific journals and has been appointed by President Bush to a six-year term on the National Cancer Advisory Board to help shape cancer policy.
Carlo M. Croce, MD, Professor, member of the National Academy of Sciences, Director of Comprehensive Cancer Center, Chair, Molecular Virology, Immunology & Medical Genetics, The Ohio State University, Columbus, OH
Honors & Awards
Chi Van Dang, M.D., Ph.D. Professor, Vice Dean for Research, the Johns Hopkins University School of Medicine, Baltimore, MD
Dr. Dang has written more than 200 scientific papers. He is senior editor of Cancer Research and serves on the editorial boards of eight other scientific publications, including the Journal of Molecular Medicine, Current Cancer Therapy Reviews, Drug Discovery Today: Disease Mechanisms, Journal of Clinical Investigations, Neoplasia, Clinical and Translational Science and The Vietnamese Medical Journal. Elected to the National Academy of Sciences' Institute of Medicine in 2006, Dr. Dang has received the National Institutes of Health/National Cancer Institute MERIT award and numerous other accolades.
DePinho, MD, Member of the National Academy of Sciences, Past President, The University of Texas MD Anderson Cancer Center, Houston, TX, and Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.
His recent Awards includes Albert Szent-Gyrgyi Prize for Progress in Cancer Research, 2009; Helsinki Medal, 2007; Albert Einstein College of Medicine Distinguished Alumnus Award, 2004; American Cancer Society Edith A. Pistorino Research Professorship, 2004; Member, Institute of Medicine of the National Academies, 2004; AACR-G.H.A. Clowes Memorial Award, 2003
Brian J. Druker, MD, PhD, member of the National Academy of Sciences, Professor, Oregon Health & Science University, Director, OHSU Knight Cancer Institute, Oregon Health & Science University
Dr. Druker is the director of OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, and professor of medicine. In 2009 he won the Lasker Clinical Award and the Meyenburg Cancer Research Prize for his influential work in the development of STI571, commonly known as Gleevec, for the treatment of Chronic Myeloid Leukemia. Dr. Druker is an investigator of Howard Hughes Medical Institute (HHMI), and was elected to the Institute of Medicine of National Academies in 2003, the American Association of Physician in 2006, and the National Academy of Sciences in 2007.
Michael A. Dyer, PhD, Professor/Member, St. Jude Faculty, Co-Leader, Developmental Therapeutics for Solid Malignancies Program
Andrew Feinberg, MD, MPH, King Fahd Professor of Molecular Medicine Department of Medicine, Department of Oncology and Department of Molecular Biology & Genetics, Johns Hopkins University School of Medicine
Dean W. Felsher, MD, PhD, Stanford University School of Medicine, Stanford, CA
Antonio Giordano, MD, Ph.D, Professor and Director, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA
He has published over 350 papers on his work in the fields of cell cycle, gene therapy and the genetics of cancer. Giordano has been named a Knight of the Republic of Italy for outstanding achievements in cancer research. In September of 2009, Giordano received the Philip Mazzei "The Bridge" Award from The American University of Rome for his scientific and economic contributions to the United States and Italy. In the past three years, Dr. Giordano's work has been profiled in Philadelphia Magazine, Philadelphia Business Journal, and Science.
President & CEO of Roswell Park Comprehensive Cancer Center, the Wallace Family Chair in Translational Research, and Professor of Oncology.
Michael Karin, Ph.D, member of the National Academy of Sciences, Professor of Pharmacology at the University of California, San Diego (UCSD; La Jolla, CA)
Dr. Karin has received numerous awards including the Oppenheimer Award for Excellence in Research from the Endocrine Society, The Herman Beerman Lectureship from the Society of Investigative Dermatology, C.E.R.I.E.S. Research Award for Physiology or Biology of the Skin, The Grossman Lectureship form the American Gastroenterology Association and an American Cancer Society Research Professorship in 1999. Dr. Karin was elected to the National Academy of Sciences in 2005. Dr. Karin also serves on several advisory boards and was cofounder of Signal Pharmaceuticals (currently Celgene).
Scott E. Kern, M.D., Professor of Oncology, Johns Hopkins University, Baltimore, MD, co-director of the Kimmel Cancer Center Gastrointestinal Cancer Program, Everett and Marjorie Kovler Professor of Pancreas Cancer Research.
Dr. Kern is a molecular geneticist interested in the clonal mutations of cancer, especially pancreatic cancer. His laboratory identified the first human Smad gene, SMAD4, as well as the first cancer mutations in Smad4, BRCA2, and other genes. Current interests include pharmacogenomics, mitotic instability, and the clinical significance of cancer biomarkers.
Guido Kroemer, Professor, Faculty of Medicine of the University of Paris Descartes, Director of the research team "Apoptosis, Cancer and Immunity" of the French Medical Research Council (INSERM).
John S. Lazo, PhD, Harrison Distinguished Professor, Departments of Pharmacology & Chemistry, Associate Director for Basic Science, UVA Cancer Center; Adjunct Professor Virginia Tech Carilion Research Institute
Arnold J. Levine, Ph.D. Member of the National Academy, Professor, The Simons Center for Systems Biology in the School of Natural Sciences at the Institute for Advanced Study, Princeton, NJ.
Levine was on the faculty of the Biochemistry Department of Princeton University from 1968 to 1979, when he became chair and professor in the Department of Microbiology at the State University of New York, Stony Brook, School of Medicine. Returning to Princeton University in 1984, he was named Harry C. Wiess Professor in the Life Sciences in the Department of Molecular Biology, a position he held until 1998. He chaired the Department between 1984 and 1996. He was President and Chief Executive Officer of the Rockefeller University in New York City from 1998 to 2002, as well as Heilbrunn Professor of Cancer Biology and laboratory head until joining the Institute in 2002. The recipient of many honors including: the Medal for Outstanding Contributions to Biomedical Research from Memorial Sloan-Kettering Cancer Center (2000); the Keio Medical Science Prize of the Keio University Medical Science Fund, Japan (2000); the Albany Medical Center Prize in Medicine and Biomedical Research (2001); and the Award for Basic Research from the Surgical Society of Oncologists (2003). Levine is a member of the National Academy of Sciences and of the Academy's Institute of Medicine; he is also the author or coauthor of over 300 scientific papers, as well as a book, Viruses (1993). He has served as board member or adviser to numerous scientific organizations and educational institutions, among them the N.J. Biotechnology Institute, the American Cyanamid Corporation, the SUNY Health Sciences Center in Brooklyn, Albert Einstein College of Medicine, the Weizmann Institute,the Huntsman Cancer Center of the University of Utah, and the Institute for Cancer Research in Lausanne, Switzerland.
Professor Lisanti, M.D., Ph.D. serves as the Director of the Manchester Breakthrough Breast Cancer Research Unit and holds the Muriel Edith Rickman Chair of Breast Oncology within the Institute of Cancer Sciences. He is also Professor of Cancer Biology and the new founding Director of the Manchester Centre for Cellular Metabolism (MCCM).
Dr. Melino is Full Professor of Molecular Biology at the University of Rome “Tor Vergata” in Italy. He also currently works as Programme Leader for the Medical Research Council Toxicology Unit, in Leicester, UK.
Harold L. Moses, PhD, Professor, Vanderbilt-Ingram Cancer Center, Nashville, TN
Dr. Nakamura received his MD and PhD from Osaka University, and became Head of the Biochemistry Department, at the Cancer Institute, Japanese Foundation for Cancer Research in 1989. He was appointed as a professor at the Institute of Medical Science, University of Tokyo in 1994 and the Department of Medicine at the University of Chicago in 2012. From January to December 2011, Dr. Nakamura was Special Advisor to the Cabinet Secretary General, Office of Medical Innovation, Cabinet Secretariat, Government of Japan. Dr. Nakamura received the Keio Medical Science Prize and the Tomizo Yoshida Award of the Japanese Cancer Association. He is a member of the Association of American Physicians.
Dr. Yusuke Nakamura discovered the APC (Familial Adenomatous Polyposis) tumor suppressor. Dr. Nakamura plays the leading role in the field of personalized medicine. He authored 1200 scientific articles.
Joseph Nevins, PhD, Professor, Duke University, Durham, NC
Pier Paolo Pandolfi, PhD, Professor, Harvard Medical School, Boston, MA
George C. Reisman Professor of Medicine and Professor of Pathology, Medicine, Harvard Medical School
Chief, Division of Genetics, Dept of Medicine, Beth Israel Deaconess Medical Center
Director, Cancer Center, Beth Israel Deaconess Medical Center
Director, Cancer Research Institute, Beth Israel Deaconess Medical Center
Nickolas Papadopoulos, Ph.D. Associate Professor, Department of Oncology, Director of Translational Genetics, Ludwig Center for Cancer Genetics & Therapeutics, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Institutions, CRB1, Room 585, 1650 Orleans Street, Baltimore, MD 21231
Jeffrey Pollard, PhD, Professor, Albert Einstein College of Medicine, Bronx, NY
Carol Prives, Ph.D, member of the National Academy of Sciences, Professor, Columbia University, New York, NY
Edward V. Prochownik, MD, PhD, Professor of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Director of Oncology Research, Children's Hospital of Pittsburgh, PA
Dr. John C. Reed, M.D., Ph.D. has been the Head of Roche Pharma Research & Early Development (Pred) at Roche Holding AG since April 2, 2013. He is an Adjunct professor at the University of California San Diego (UCSD) Department of Molecular Pathology, University of Florida, University of Central Florida, and in San Diego State University's Biology department.
Neal Rosen, M.D., Ph.D. is a Member in the Department of Medicine and in the Molecular Pharmacology and Chemistry Program at Memorial Sloan-Kettering Cancer Center, where he serves as Head of Developmental Therapeutics. He is also a Professor of Pharmacology, Cell Biology and Medicine at Cornell University Medical School.
Andrew V. Schally won the Nobel Prize for Medicine or Physiology in 1977, for his research into peptide hormone production in the brain. He is currently Distinguished Medical Research Scientist of the Department of Veterans Affairs, Head of the Endocrine, Polypeptide and Cancer Institute Veterans Affairs Medical Center, Research Service Miami, FL and South Florida VA Foundation for Research and Education, Distinguished Leonard Miller Professor of Pathology, Professor Division of Hematology/Oncology and Division of Endocrinology Department of Medicine, Miller School of Medicine, University of Miami, FL.
Dr. Schally was one of a pair of scientists to first isolate several of the communicating chemical links between the brain and the pituitary gland and also determined their structure and succeeded in synthesizing them. Schally’s discoveries have led to many practical clinical applications that are in wide use. He has written over 2,200 publications, more than 1,200 of them since receiving the Nobel Prize. 27 European & South American Universities: M.D.H.C., D.H.C., D.Sc.H.C., D.Nat. Sc. H.C.
Lasker Award 1975
Nobel Prize in Physiology or Medicine, 1977
Gregg L. Semenza, M.D., Ph.D, member of the National Academy of Sciences, Professor, Johns Hopkins University School of Medicine, Baltimore, MD
Donald L. (Skip) Trump, MD, FACP, is CEO and executive director of Inova Schar Cancer Institute. Prior to joining Inova, Dr. Trump was president and CEO of Roswell Park Comprehensive Cancer Center in Buffalo, NY.
Alexander Varshavsky, Ph.D, member of the National Academy of Sciences, Professor, California Institute of Technology, Pasadena, CA
Alexander Varshavsky is a recipient of the Albert Lasker Award for Basic Medical Research, the Wolf Prize in Medicine and the Louisa Gross Horwitz Prize from Columbia University in 2001 for his research on ubiquitination. In 2006 he won the March of Dimes Prize in Developmental Biology and he won the 2007 $1 million Gotham Prize for an original approach to killing cancer cells.
Bert Vogelstein, M.D., member of the National Academy of Sciences, Professor, Johns Hopkins University, Baltimore, MD
Bert Vogelstein is a Howard Hughes Medical Institute investigator. He has received the Gairdner Foundation International Award, Louisa Gross Horwitz Prize from Columbia University, Prince of Asturias Award for Technical and Scientific Research, and other awards for his research.
Peter K. Vogt, Ph.D, member of the National Academy of Science, Professor, The Scripps Research Institute, La Jolla, CA
Dr. Vogt is a Professor in the Department of Molecular and Experimental Medicine at The Scripps Research Institute in La Jolla, California. He has received many awards and honors, including the Gregor Johann Mendel Medal, Charles S. Mott Prize, Ernst Jung Prize for Medicine, Bristol Meyers Award, and ICN International Prize in Virology. Dr. Vogt has been invited as a distinguished lecturer by more than twenty leading research institutions in the US, Europe, and Asia, among them the German Cancer Research Center in Heidelberg for the Meyenburg Foundation Lecture, the Princess Takamatsu Foundation, the Alexander von Humboldt Foundation of the Federal Republic of Germany and the Agency for Science, Technology and Research of Singapore. He was also elected an Honorary Member of the Japanese Cancer Association and received an honorary doctorate from the University of Würzburg. Dr. Vogt is an elected member of many prestigious academies, including the American Academy of Arts and Sciences, the National Academy of Sciences, the Institute of Medicine of the National Academies, and the American Academy of Microbiology. He is the recipient of the 5th Annual Szent-Györgyi Prize for Progress in Cancer Research.
Paul Workman, The Institute of Cancer Research, London, UK
Dr. Zeng Yixin, Professor and Director, Cancer Center and the State Key Laboratory of Oncology in Southern China, Sun Yat-sen University, Guangzhou, China.
He was elected as a member of the Chinese Academy of Sciences in 2005. Besides, Professor Zeng also has many other academic positions including the Vice President of the China Anti-Cancer Association, President of the Board of the International Society on Epstein-Barr Virus & Related Diseases (2006-2008), a member of the Third World Academy of Sciences, and a member of the Europe-Asian Academy of Sciences
Two members of Oncotarget Editorial Board are Nobel Prize winners : Andrew V. Schally ( Physiology or Medicine 1977); Gregg L. Semenza ( Physiology or Medicine 2019)
Since 2013, four members of Oncotarget/Oncoscience/Gerotarget have won the Breakthrough Prize, the highest prize ever: Bert Vogelstein, Michael N. Hall, Alexander Varshavsky, Stephen J. Elledge
It is with sadness that we share the passing of our Editorial Board Member, Arthur B. Pardee, who died February 24, 2019 at the age of 97.
Dr. Pardee (1921-2019), member of the National Academy of Sciences, Professor of Biological Chemistry and Molecular Pharmacology Emeritus, Harvard Medical School, was a renowned cancer biologist who made several groundbreaking discoveries in the mid-20th century that shaped modern molecular biology.
We have been honored to have Dr. Pardee as a Founding Editor of Oncotarget.
It is with great sadness that we share the passing of Joseph R. Bertino, MD, the founding Editor of Oncotarget.
For more than 50 years, Joseph R. Bertino, MD, has devoted his life to improving therapies for cancer and hematologic disorders and has contributed his expertise toward establishing the foundation of modern cancer research. Dr. Bertino is internationally recognized for his role in finding curative treatments for leukemia and lymphoma. He was the past president of The American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO). He received many awards throughout his career including, but not limited to, the AACR Lifetime Achievement in Cancer Research Award, the University of Texas MD Anderson Cancer Center Jeffrey A. Gottlieb Memorial Award, and the LRF Key to the Cure Award and Freundlich Leadership Award.
Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC